Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
Non-small cell lung cancer (NSCLC) is one of the most commonly diagnosed cancers and the leading cause of cancer-related deaths in China. NSCLC has one of the most dynamic drug development pipelines in oncology with multiple targeted and biomarker-driven therapies. Notably, many targeted therapies are intended for patients with activating EGFR mutations, which are more prevalent in China than in the western markets. DRG expects the Chinese NSCLC therapy market to experience robust growth throughout the 2018-2028 forecast period. The biggest driver of market sales growth will be the continued uptake and anticipated approvals of immune checkpoint inhibitors. EGFR and ALK inhibitor drug classes will also drive market growth following the incorporation of several therapies into China’s National Reimbursement Drug List, thereby securing access to patients in need. Notable novel therapies from different drug classes, including four inhibitors for patients harboring either EGFR or ALK mutations, are expected to gain approval within the forecast period, resulting in increased therapy options and potent market growth.
China In-Depth: Comprehensive market intelligence providing world-class epidemiology, keen insight into the China specific access & reimbursement environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Qualitative and quantitative insights driven by 5 country-specific interviews with thought-leading medical oncologists Supported by survey data collected for this and other DRG research epidemiology Diagnosed incidence of NSCLC by ALK and EGFR biomarkers status and by disease stage. Clinically and market relevant drug-treatable populations.
10-year, annualized, drug-level sales and patient shares of key NSCLC regimens through 2028, based on primary and secondary market research to formulate bottom-up assumptions
Phase III/PR: 6 drugs. Phase II: 1 drugs. Coverage of select early-phase products.
Already a Client? Log in to access this report.
Steve is a member of Decision Resources Group’s Infectious, Niche, and Rare Diseases (INRD) team. Currently, he provides analyses and content production on infections caused by the human immunodeficiency virus (HIV) and the hepatitis C virus (HCV). Steve conducted his postdoctoral research on models of neurodegenerative disease in the Department of Biochemistry at Brandeis University. He earned a doctorate in biochemistry from the University of Massachusetts Medical School, Graduate School of Biomedical Sciences, where he studied protein translocation into the endoplasmic reticulum.
Atul Sharma started working in Decision Resources Group as an intern in early 2016 and currently works as an associate epidemiologist. He performs fully documented systematic reviews of both published and grey literature on the epidemiology of assigned diseases and their risk factors to estimate incidence/prevalence over a 10-30 year period. He produces analyses for pharmaceutical drug developers on the descriptive epidemiology of major drug indications in mature and developing markets. He holds a Master’s in Public Health degree from School of Public Health, Post-Graduate Institute of Medical Education and Research and a Bachelor’s in dental surgery from MN DAV Dental College & Hospital.
Meghan Hennis, PhD is a Senior Analyst in the New Product Development group at Decision Resources Group. She has over 10 years of research experience in the biological sciences followed by 2 years as part of the Consulting team at DRG where she provided key insights to client business questions across a range of therapeutic areas. Dr. Hennis received her in Neuroscience from University of Texas Southwestern Medical Center and her in Biology from University of North Carolina Chapel Hill.